News

Irit Ben-Aharon, MD, PhD, Fishman Oncology Center

Videos

Increasing Incidence of Early-Onset Colorectal Cancer

08/28/2023

At the 2023 World Congress on Gastrointestinal Cancers, Irit Ben-Aharon, MD, PhD discussed how the incidence of early-onset colorectal cancer has risen over the past 2 decades.

At the 2023 World Congress on...

08/28/2023

Oncology

Josep Tabernero, MD, PhD, Vall d'Hebron Barcelona Hospital Campus

Videos

Sequencing of Encorafenib Plus Cetuximab Among Patients With BRAF-Mutant Metastatic Colorectal Cancer

08/25/2023

Josep Tabernero , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Josep Tabernero, MD, PhD presented a post hoc analysis of the BEACON trial that evaluated differences among patients with BRAF V600E-mutant metastatic colorectal cancer treated with...

At the 2023 World Congress on...

08/25/2023

Oncology

Thierry André, MD, Saint-Antoine Hospital

Videos

Integrating Checkpoint Inhibitors into Treatment of Patients MSI-High Rectal Cancer

08/24/2023

Thierry André , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Thierry André, MD, discussed the use of checkpoint inhibitors for patients with MSI-high colorectal cancer.

At the 2023 World Congress on...

08/24/2023

Oncology

Sabine Tejpar, MD, PhD, University Hospitals Leuven

Videos

Single Cell Analysis and Transcriptomics in Colorectal Cancer

08/24/2023

Sabine Tejpar , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Sabine Tejpar, MD, PhD, explained the application of single cell analyses in colorectal cancer.

At the 2023 World Congress on...

08/24/2023

Oncology

Guillem Argiles, MD, Memorial Sloan Kettering Cancer Center

Videos

Mechanisms of Response to Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer

08/24/2023

G. Argiles ;

At the 2023 World Congress on Gastrointestinal Cancers, Guillen Argiles, MD, discussed the mechanisms of response to immune checkpoint inhibitors in colorectal cancer.

At the 2023 World Congress on...

08/24/2023

Oncology

Erika Martinelli, MD, PhD, Università degli Studi della Campania “L. Vanvitelli”

Videos

Upcoming Advancements in the Treatment of BRAF-Mutant, Metastatic Colorectal Cancer

08/23/2023

Erika Martinelli , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Erika Martinelli, MD, PhD, highlighted key upcoming advancements for the treatment of BRAF-mutant metastatic colorectal cancer.

At the 2023 World Congress on...

08/23/2023

Oncology

Alberto Sobrero, MD, Ospedale San Martino

Videos

Groundbreaking Advancements in Colorectal Cancer From the Past 25 Years

08/23/2023

Alberto F. Sobrero , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Alberto Sobrero, MD, highlighted key advancements in colorectal cancer from the past 25 years.

At the 2023 World Congress on...

08/23/2023

Oncology

Alfonso De Stefano, MD, PhD, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale

Videos

Intermittent vs Continuous Panitumumab Plus FOLFIRI for First-Line Treatment of Patients With RAS/BRAF Wild-Type Colorectal Cancer

08/21/2023

Alfonso De Stefano , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Alfonso De Stefano, MD, PhD presented results of the IMPROVE study on intermittent or continuous panitumumab plus FOLFIRI for the first-line treatment of patients with RAS/BRAF wild-type...

At the 2023 World Congress on...

08/21/2023

Oncology

Eric Lander, MD, Vanderbilt University Medical Center

Videos

Tumor Mutational Signatures Among Patients With Early-Onset Versus Average-Onset Colorectal Cancer

08/21/2023

Eric Lander , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Eric Lander, MD, presents genomic clustering data suggesting that early-onset colorectal cancer may be caused by unique mutagenic processes compared to average-onset colorectal cancer.

At the 2023 World Congress on...

08/21/2023

Oncology

Muhammad Danyal Ahsan, New York Presbyterian Hospital, Weill Cornell Medicine

Videos

Mutational Landscape of Homologous Recombination Deficiency Pathogenic Gene Variants in Colorectal Cancer

08/18/2023

Muhammad Danyal Ahsan ;

At the 2023 World Congress on Gastrointestinal Cancers, Muhammad Danyal Ahsan discusses results from a study that utilized the GENIE database to determine the potential utility of widespread functional HRD status assessment in colorectal...

At the 2023 World Congress on...

08/18/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology